The raw feed
Latest filings
Every transaction from every Form 4, as filed, newest first. Open-market buys (P) and sells (S) become signals; the rest is shown for completeness.
| Date | Company | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | ZM Zoom Video Communications, Inc. | Eric S. Yuan Chief Executive Officer | CConversion Class B Common Stockderivativeindirect: See footnote10b5-1 | -12,100 | $0.00 | $0 | 20,704,185 | Aug 7, 2026 |
| Aug 6, 2026 | ZM Zoom Video Communications, Inc. | Eric S. Yuan Chief Executive Officer | CConversion Class B Common Stockderivativeindirect: See footnote10b5-1 | -12,100 | $0.00 | $0 | 20,692,085 | Aug 7, 2026 |
| Aug 5, 2026 | DDOG Datadog, Inc. | Olivier Pomel Chief Executive Officer | CConversion Class A Common Stock10b5-1 | +127,141 | $0.00 | $0 | 739,888 | Aug 7, 2026 |
| Aug 5, 2026 | DDOG Datadog, Inc. | Olivier Pomel Chief Executive Officer | CConversion Class B Common Stockderivative10b5-1 | -127,141 | $0.00 | $0 | 8,793,243 | Aug 7, 2026 |
| Aug 7, 2026 | BRVE Braveheart Bio, Inc. | Forbion Growth Opportunities Fund III Cooperatief U.A. owner | CConversion Common Stock | +9,132,420 | $0.00 | $0 | 9,720,546 | Aug 7, 2026 |
| Aug 7, 2026 | BRVE Braveheart Bio, Inc. | Forbion Growth Opportunities Fund III Cooperatief U.A. owner | CConversion Common Stockindirect: By Forbion Ventures Fund VII Cooperatief U.A. | +7,990,867 | $0.00 | $0 | 8,505,478 | Aug 7, 2026 |
| Aug 7, 2026 | BRVE Braveheart Bio, Inc. | Forbion Growth Opportunities Fund III Cooperatief U.A. owner | CConversion Series A Preferred Stockderivative | -40,000,000 | $0.00 | $0 | 0 | Aug 7, 2026 |
| Aug 7, 2026 | BRVE Braveheart Bio, Inc. | Forbion Growth Opportunities Fund III Cooperatief U.A. owner | CConversion Series A Preferred Stockderivativeindirect: By Forbion Ventures Fund VII Cooperatief U.A. | -35,000,000 | $0.00 | $0 | 0 | Aug 7, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Sanofi owner | CConversion Common Stockindirect: See footnote | +782,855 | - | - | 782,855 | Aug 7, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Sanofi owner | CConversion Series C Preferred Stockderivativeindirect: See footnote | -782,855 | - | - | 0 | Aug 7, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Redmile Group, LLC owner | CConversion Common Stockindirect: See footnotes | +782,854 | - | - | 782,854 | Aug 7, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Redmile Group, LLC owner | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -782,854 | - | - | 0 | Aug 7, 2026 |
| Aug 7, 2026 | BATL BATTALION OIL CORP | Gen IV Investment Opportunities, LLC owner | CConversion Common Stock | +253,815 | $0.00 | $0 | 253,815 | Aug 7, 2026 |
| Aug 7, 2026 | BATL BATTALION OIL CORP | Gen IV Investment Opportunities, LLC owner | CConversion Common Stock | +1,607,845 | $0.00 | $0 | 1,861,660 | Aug 7, 2026 |
| Aug 7, 2026 | BATL BATTALION OIL CORP | Gen IV Investment Opportunities, LLC owner | CConversion Common Stock | +799,216 | $0.00 | $0 | 2,660,876 | Aug 7, 2026 |
| Aug 7, 2026 | BATL BATTALION OIL CORP | Gen IV Investment Opportunities, LLC owner | CConversion Common Stock | +833,383 | $0.00 | $0 | 3,494,259 | Aug 7, 2026 |
| Aug 7, 2026 | BATL BATTALION OIL CORP | Gen IV Investment Opportunities, LLC owner | CConversion Series A-1 Redeemable Convertible Preferred Stockderivative | -1,232 | $0.00 | $0 | 0 | Aug 7, 2026 |
| Aug 7, 2026 | BATL BATTALION OIL CORP | Gen IV Investment Opportunities, LLC owner | CConversion Series A-2 Redeemable Convertible Preferred Stockderivative | -6,630 | $0.00 | $0 | 0 | Aug 7, 2026 |
| Aug 7, 2026 | BATL BATTALION OIL CORP | Gen IV Investment Opportunities, LLC owner | CConversion Series A-3 Redeemable Convertible Preferred Stockderivative | -3,789 | $0.00 | $0 | 0 | Aug 7, 2026 |
| Aug 7, 2026 | BATL BATTALION OIL CORP | Gen IV Investment Opportunities, LLC owner | CConversion Series A-4 Redeemable Convertible Preferred Stockderivative | -3,789 | $0.00 | $0 | 0 | Aug 7, 2026 |
| Aug 6, 2026 | MDLN Medline Inc. | Mozart Holdco, Inc. owner | CConversion Class A Common Stock | +500,000 | $0.00 | $0 | 787,648 | Aug 7, 2026 |
| Aug 6, 2026 | MDLN Medline Inc. | Mozart Holdco, Inc. owner | CConversion Common Units of Medline Holdings, LPderivative | -500,000 | $0.00 | $0 | 233,520,656 | Aug 7, 2026 |
| Aug 4, 2026 | CRWV CoreWeave, Inc. | Michael N Intrator CEO and President | CConversion Class A Common Stockindirect: Omnadora Capital LLC10b5-1 | +107,692 | - | - | 107,692 | Aug 6, 2026 |
| Aug 4, 2026 | CRWV CoreWeave, Inc. | Michael N Intrator CEO and President | CConversion Class B Common Stockderivativeindirect: Omnadora Capital LLC10b5-1 | -107,692 | - | - | 22,910,816 | Aug 6, 2026 |
| Aug 4, 2026 | DDOG Datadog, Inc. | Michael James Callahan director | CConversion Class A Common Stockindirect: By Trust10b5-1 | +12,500 | $0.00 | $0 | 27,496 | Aug 6, 2026 |
| Aug 4, 2026 | DDOG Datadog, Inc. | Michael James Callahan director | CConversion Class B Common Stockderivativeindirect: By Trust10b5-1 | -12,500 | $0.00 | $0 | 85,542 | Aug 6, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Frazier Life Sciences XI, L.P. owner | CConversion Common Stock | +1,749,192 | - | - | 1,824,541 | Aug 6, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Frazier Life Sciences XI, L.P. owner | CConversion Common Stock | +1,590,175 | - | - | 3,414,716 | Aug 6, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Frazier Life Sciences XI, L.P. owner | CConversion Common Stock | +1,189,940 | - | - | 4,604,656 | Aug 6, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Frazier Life Sciences XI, L.P. owner | CConversion Common Stock | +961,322 | - | - | 5,565,978 | Aug 6, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Frazier Life Sciences XI, L.P. owner | CConversion Series A-1 Preferred Stockderivative | -16,250,000 | $0.00 | $0 | 0 | Aug 6, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Frazier Life Sciences XI, L.P. owner | CConversion Series A-2 Preferred Stockderivative | -14,772,727 | $0.00 | $0 | 0 | Aug 6, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Frazier Life Sciences XI, L.P. owner | CConversion Series B Preferred Stockderivative | -11,054,544 | $0.00 | $0 | 0 | Aug 6, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Frazier Life Sciences XI, L.P. owner | CConversion Series C Preferred Stockderivative | -8,930,685 | $0.00 | $0 | 0 | Aug 6, 2026 |
| Aug 4, 2026 | LIFE Ethos Technologies Inc. | Accel Growth Fund IV L.P. owner | CConversion Class A Common Stock | +1,695,244 | - | - | 1,695,244 | Aug 6, 2026 |
| Aug 4, 2026 | LIFE Ethos Technologies Inc. | Accel Growth Fund IV L.P. owner | CConversion Class A Common Stockindirect: By Accel Growth Fund Investors 2016 L.L.C. | +81,083 | - | - | 81,083 | Aug 6, 2026 |
| Aug 4, 2026 | LIFE Ethos Technologies Inc. | Accel Growth Fund IV L.P. owner | CConversion Class A Common Stockindirect: By Accel Growth Fund IV L.P. Strategic Partners L.P. | +9,644 | - | - | 9,644 | Aug 6, 2026 |
| Aug 4, 2026 | LIFE Ethos Technologies Inc. | Accel Growth Fund IV L.P. owner | CConversion Class B Common Stockderivative | -1,695,244 | $0.00 | $0 | 5,085,731 | Aug 6, 2026 |
| Aug 4, 2026 | LIFE Ethos Technologies Inc. | Accel Growth Fund IV L.P. owner | CConversion Class B Common Stockderivativeindirect: By Accel Growth Fund Investors 2016 L.L.C. | -81,083 | $0.00 | $0 | 243,255 | Aug 6, 2026 |
| Aug 4, 2026 | LIFE Ethos Technologies Inc. | Accel Growth Fund IV L.P. owner | CConversion Class B Common Stockderivativeindirect: By Accel Growth Fund IV Strategic Partners L.P. | -9,644 | $0.00 | $0 | 28,929 | Aug 6, 2026 |
| Aug 4, 2026 | PROK PROKIDNEY CORP. | Brian JG Pereira director | CConversion Class A Common Stock | +81,929 | $0.00 | $0 | 81,929 | Aug 6, 2026 |
| Aug 4, 2026 | PROK PROKIDNEY CORP. | Brian JG Pereira director | CConversion Class A Common Stockindirect: By Brian J. G. Pereira 2012 Irrevocable Trust | +675,235 | $0.00 | $0 | 675,235 | Aug 6, 2026 |
| Aug 4, 2026 | PROK PROKIDNEY CORP. | Brian JG Pereira director | CConversion Class B Common Stockderivative | -81,929 | $0.00 | $0 | 0 | Aug 6, 2026 |
| Aug 4, 2026 | PROK PROKIDNEY CORP. | Brian JG Pereira director | CConversion Common Units in ProKidney Holdings, LLCderivative | -81,929 | $0.00 | $0 | 0 | Aug 6, 2026 |
| Aug 4, 2026 | PROK PROKIDNEY CORP. | Brian JG Pereira director | CConversion Class B Common Stockderivativeindirect: By Brian J. G. Pereira 2012 Irrevocable Trust | -675,235 | $0.00 | $0 | 0 | Aug 6, 2026 |
| Aug 4, 2026 | PROK PROKIDNEY CORP. | Brian JG Pereira director | CConversion Common Units in ProKidney Holdings, LLCderivativeindirect: By Brian J. G. Pereira 2012 Irrevocable Trust | -675,235 | $0.00 | $0 | 0 | Aug 6, 2026 |
| Aug 3, 2026 | RBRK Rubrik, Inc. | Arvind Nithrakashyap Chief Technology Officer | CConversion Class A Common Stock10b5-1 | +2,502 | $0.00 | $0 | 306,113 | Aug 5, 2026 |
| Aug 4, 2026 | RBRK Rubrik, Inc. | Arvind Nithrakashyap Chief Technology Officer | CConversion Class A Common Stock10b5-1 | +12,820 | $0.00 | $0 | 306,113 | Aug 5, 2026 |
| Aug 5, 2026 | RBRK Rubrik, Inc. | Arvind Nithrakashyap Chief Technology Officer | CConversion Class A Common Stock10b5-1 | +12,820 | $0.00 | $0 | 306,113 | Aug 5, 2026 |
| Aug 3, 2026 | RBRK Rubrik, Inc. | Arvind Nithrakashyap Chief Technology Officer | CConversion Class B Common Stockderivative10b5-1 | -2,502 | $0.00 | $0 | 10,092,350 | Aug 5, 2026 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.